The purpose of this post-marketing study is to assess the amount of guselkumab in breast milk of lactating women receiving guselkumab as part of their standard clinical care provided by their treating physician, for any of the approved indications.

Massachusetts General Hospital is conducting a research study to develop and assess the feasibility and effect of a web-based, personalized risk-estimation for CD (PRE-Crohn’s) tool on behaviors and biomarkers associated with CD in unaffected first-degree relatives (FDRs) of patients with inflammatory bowel disease. 

This study is being done because we need to find out how safe the study drug (vedolizumab) is and how it is used up by the body in different ages of children. This study is to find out how the [vedolizumab] study drug works inside you after it has been injected into your body. 

This study is designed to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease.

The purpose of this Phase 2a study is to evaluate the efficacy of MK-8690 in participants with moderately to severely active ulcerative colitis. 

The purpose of this study is to investigate the efficacy & safety of intravenous infusions of allogeneic (from an approved donor) HB-adMSCs (adipose-derived mesenchymal stem cells) vs placebo in patients with Crohn's Disease.

To evaluate the safety and efficacy of an oral investigational medication in people with moderately to severely active Crohn’s disease (CD).

The main purpose of this study is to see if the study drug is safe and effective in treating your CD, and whether it is safe when given for an extended period of time.

This is a Phase 2 study. This means that the study drug has already been tested in small numbers of healthy volunteers. In addition, the study drug has been tested in patients with other medical conditions, including ulcerative colitis (another inflammatory bowel disease). This study is now testing the study drug in a group of patients with CD.

To evaluate the safety and efficacy of an oral investigational medication in people with moderately to severely active ulcerative colitis.

This research study is being done to learn more about CLF065 as a potential treatment for chronic pouchitis. The purpose is to learn about the safety of CLF065, and how well a weekly dose of CLF065 treats chronic pouchitis.